Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
In pharmaceutical manufacturing, “boosting the flow” can mean improving how materials move through production. This article focuses on continuous manufacturing, not drug distribution or supply-chain logistics: a process that continuously feeds inputs, transforms material and removes outputs. It can connect multiple operations into an integrated production system, but it does not guarantee a particular increase in speed, capacity or quality.
What is continuous manufacturing in pharma?
The U.S. Food and Drug Administration (FDA) describes continuous manufacturing as the ongoing feeding of inputs, transformation of in-process materials and removal of outputs. Its guidance focuses on integrated processes in which two or more unit operations are directly connected. That distinction matters: a single operation running continuously is not necessarily the integrated system addressed by the guidance.
In its March 2023 guidance, FDA describes Q13 as addressing the “development, implementation, operation, and lifecycle management” of continuous manufacturing. The guidance covers drug substances and drug products made from chemical entities and therapeutic proteins. It applies to new products and to conversion of existing products from batch manufacturing; its principles may also apply to other biological or biotechnological entities.
How does continuous manufacturing differ from batch production?
The main difference is process architecture. Batch production handles material in defined batches, while continuous manufacturing maintains material movement through connected operations. The comparison is about how production is organized—not a universal ranking of which approach performs better.
#1 Best Overall
| Factor | Batch manufacturing | Continuous manufacturing |
|---|---|---|
| Process architecture | Production is organized into separate batches. | Inputs, transformations and outputs move through the process on an ongoing basis. |
| Integration | Operations are organized around batch handling; the degree of connection depends on the process. | FDA Q13 focuses on systems directly connecting two or more unit operations. |
| Monitoring and control | Must be appropriate to the process and its quality requirements. | Must address process dynamics, disturbances, monitoring, control and material handling across the connected system. |
| Nonconforming material | Handling depends on the process and quality system. | The system needs strategies to identify and divert material that does not meet requirements. |
| Performance outcome | No universal speed, cost or quality advantage is established. | No universal speed, cost or quality advantage is established. |
Neither approach is inherently best for every product or process. Product and process suitability, integration requirements, disturbance response and lifecycle-management needs all matter. FDA’s Q13 framework does not promise a particular throughput gain, and the available FDA materials do not establish a cross-industry percentage improvement in speed, cost or quality.
How can pharmaceutical manufacturers improve production flow?
Continuous manufacturing changes how material moves, but effective flow depends on controlling the process as a connected system. Manufacturers need to understand how the process behaves, recognize when conditions change and decide what happens to material affected by a deviation.
- Characterize process dynamics: understand how the connected operations behave over time and respond to changes.
- Plan for disturbances and raw-material variation: assess how variations or disruptions can affect process conditions and downstream material.
- Monitor and control the process: establish suitable ways to detect deviations and maintain control across operations.
- Manage material collection and diversion: determine how material is handled, including how potentially nonconforming material is identified and diverted.
- Consider real-time release testing: evaluate whether this approach fits the product, process and control strategy; it is a consideration, not an automatic feature of continuous manufacturing.
These topics appear in FDA’s regulatory considerations for continuous manufacturing. They describe issues to address, not a checklist that by itself establishes a facility’s readiness or compliance.
What does FDA require for continuous manufacturing?
FDA’s March 2023 ICH Q13 guidance provides scientific and regulatory considerations for developing, implementing, operating and managing the lifecycle of continuous manufacturing. It addresses both new products and conversion of existing products from batch production. It is a framework for considering how an integrated process is developed and controlled—not a guarantee of approval or permission to assume that a particular design will meet regulatory expectations.
Continuous manufacturing does not replace current good manufacturing practice (CGMP). FDA describes CGMP regulations as minimum requirements for manufacturing methods, facilities and controls, and says application review includes assessment of manufacturers’ CGMP compliance. Manufacturers must therefore consider both the continuous process and the applicable quality and compliance obligations. These FDA materials describe the U.S. regulatory context; requirements elsewhere may differ.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How do process monitoring and quality metrics support pharmaceutical manufacturing?
Process monitoring helps operators and quality teams understand what is happening within production and detect deviations. Quality metrics serve a broader oversight role: FDA says they can help evaluate manufacturing performance, improve quality systems, oversee suppliers, and predict or possibly mitigate future drug shortages.
Rank #4
FDA defines quality metrics as “an objective way to measure, evaluate, and monitor the product and process lifecycle” in its Quality Metrics for Drug Manufacturing resource. Metrics are most useful when connected to the process and decisions they are meant to inform. FDA’s resource does not endorse one universal KPI for improving manufacturing flow, so a metric should not be treated as proof of better throughput on its own.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
